• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Causes and outcomes of markedly elevated C-reactive protein levels.C反应蛋白水平显著升高的原因及后果。
Can Fam Physician. 2017 Jun;63(6):e316-e323.
2
[Etiology and prognosis of highly elevated C-reactive protein levels (≥500 mg/L): a retrospective study about 168 measures in a series of 113 patients].[超高水平C反应蛋白(≥500mg/L)的病因及预后:对113例患者中168次检测的回顾性研究]
Rev Med Interne. 2011 Nov;32(11):663-8. doi: 10.1016/j.revmed.2011.04.001. Epub 2011 May 17.
3
Periodontal infections contribute to elevated systemic C-reactive protein level.牙周感染会导致全身C反应蛋白水平升高。
J Periodontol. 2001 Sep;72(9):1221-7. doi: 10.1902/jop.2000.72.9.1221.
4
Comparative evaluation of postmortem serum concentrations of neopterin and C-reactive protein.死后血清中蝶呤和C反应蛋白浓度的比较评估
Forensic Sci Int. 2008 Aug 6;179(2-3):135-43. doi: 10.1016/j.forsciint.2008.04.021. Epub 2008 Jun 9.
5
C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a 2-year prospective study.C反应蛋白和降钙素原作为血液透析患者死亡率的标志物:一项为期2年的前瞻性研究。
J Ren Nutr. 2003 Apr;13(2):137-43. doi: 10.1053/jren.2003.50017.
6
C-reactive protein in outpatients with acute exacerbation of COPD: its relationship with microbial etiology and severity.慢性阻塞性肺疾病急性加重期门诊患者的C反应蛋白:其与微生物病因及严重程度的关系
Int J Chron Obstruct Pulmon Dis. 2016 Oct 21;11:2633-2640. doi: 10.2147/COPD.S117129. eCollection 2016.
7
[Long term effect of autoadjusting positive airway pressure on C-reactive protein and interleukin-6 in men with obstructive sleep apnoea syndrome].[自动调压持续气道正压通气对阻塞性睡眠呼吸暂停低通气综合征男性患者C反应蛋白和白细胞介素-6的长期影响]
Arch Bronconeumol. 2009 Dec;45(12):577-84. doi: 10.1016/j.arbres.2009.05.002. Epub 2009 Jun 23.
8
The course of C-reactive protein response in untreated upper respiratory tract infection.未经治疗的上呼吸道感染中C反应蛋白的反应过程。
Br J Gen Pract. 2004 Sep;54(506):653-8.
9
Relationship between admission serum C-reactive protein and short term outcome following acute ischaemic stroke at a tertiary health institution in Nigeria.尼日利亚一家三级医疗机构中急性缺血性卒中患者入院时血清C反应蛋白与短期预后的关系。
Niger J Clin Pract. 2013 Jul-Sep;16(3):320-4. doi: 10.4103/1119-3077.113454.
10
Association between C-reactive protein and clinical outcomes in peritoneal dialysis patients.腹膜透析患者中C反应蛋白与临床结局的关联
Adv Perit Dial. 2005;21:154-8.

引用本文的文献

1
Evaluation of Diagnostic Efficacy of Anticyclic Citrullinated Peptide Antibody in Diagnosis of Rheumatoid Arthritis.抗环瓜氨酸肽抗体在类风湿关节炎诊断中的诊断效能评估
Int J Appl Basic Med Res. 2025 Jul-Sep;15(3):178-183. doi: 10.4103/ijabmr.ijabmr_128_25. Epub 2025 Aug 20.
2
Letter to the Editor: Intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open‑label, phase II/III study.致编辑的信:可切除胃癌术中使用皮质类固醇:一项多中心、随机、开放标签的II/III期研究
Gastric Cancer. 2025 Aug 6. doi: 10.1007/s10120-025-01652-4.
3
Hematological Changes in Pulmonary Tuberculosis: Focus on Anemia, Disease Severity, and Therapeutic Implications.肺结核的血液学变化:关注贫血、疾病严重程度及治疗意义
Cureus. 2025 Jun 22;17(6):e86550. doi: 10.7759/cureus.86550. eCollection 2025 Jun.
4
Predictors of Significant High-Sensitivity C-Reactive Protein Reduction After Use of Rosuvastatin/Amlodipine and Atorvastatin/Amlodipine-Subgroup Analysis in Randomized Controlled Trials.瑞舒伐他汀/氨氯地平与阿托伐他汀/氨氯地平在随机对照试验中的应用后高敏C反应蛋白显著降低的预测因素——亚组分析
J Clin Med. 2025 May 12;14(10):3363. doi: 10.3390/jcm14103363.
5
C-reactive protein in the first 30 postoperative days and its discriminative value as a marker for postoperative infections, a multicentre cohort study.术后30天内的C反应蛋白及其作为术后感染标志物的鉴别价值:一项多中心队列研究
BMJ Open. 2025 Apr 22;15(4):e093615. doi: 10.1136/bmjopen-2024-093615.
6
Risk factors for severe adverse drug reactions in hospitalized patients.住院患者严重药物不良反应的危险因素。
Open Med (Wars). 2025 Jan 13;20(1):20241122. doi: 10.1515/med-2024-1122. eCollection 2025.
7
Prognostic performance of early immune and endothelial activation markers in mild-to-moderate COVID-19 outpatients: a nested case-control study.轻度至中度COVID-19门诊患者早期免疫和内皮激活标志物的预后性能:一项巢式病例对照研究
Front Immunol. 2024 Nov 27;15:1501872. doi: 10.3389/fimmu.2024.1501872. eCollection 2024.
8
Exploring the role of sex hormones and gender diversity in multiple sclerosis.探索性激素和性别多样性在多发性硬化症中的作用。
Nat Rev Neurol. 2025 Jan;21(1):48-62. doi: 10.1038/s41582-024-01042-x. Epub 2024 Dec 11.
9
Inflammatory, Hematological, and Biochemical Biomarkers in COVID-19 Patients.新冠病毒肺炎患者的炎症、血液学及生化生物标志物
Immun Inflamm Dis. 2024 Dec;12(12):e70078. doi: 10.1002/iid3.70078.
10
Elevated PD-L1 and PECAM-1 as Diagnostic Biomarkers of Acute Rejection in Lung Transplantation.PD-L1和PECAM-1升高作为肺移植急性排斥反应的诊断生物标志物
Transpl Int. 2024 Nov 21;37:13796. doi: 10.3389/ti.2024.13796. eCollection 2024.

本文引用的文献

1
C-reactive protein and risk of lung cancer.C-反应蛋白与肺癌风险。
J Clin Oncol. 2010 Jun 1;28(16):2719-26. doi: 10.1200/JCO.2009.27.0454. Epub 2010 Apr 26.
2
C-reactive protein and systemic lupus erythematosus.C反应蛋白与系统性红斑狼疮
Arthritis Rheum. 2008 Dec 15;59(12):1814-20. doi: 10.1002/art.24316.
3
Extremely elevated C-reactive protein.超高水平的C反应蛋白。
Eur J Intern Med. 2006 Oct;17(6):430-3. doi: 10.1016/j.ejim.2006.02.025.
4
C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany.C反应蛋白基于弗明汉姆评分调节风险预测:对未来风险评估的启示:来自德国南部一项大型队列研究的结果
Circulation. 2004 Mar 23;109(11):1349-53. doi: 10.1161/01.CIR.0000120707.98922.E3. Epub 2004 Mar 15.
5
C-reactive protein: a critical update.C反应蛋白:重要更新
J Clin Invest. 2003 Jun;111(12):1805-12. doi: 10.1172/JCI18921.
6
Acute-phase proteins and other systemic responses to inflammation.急性期蛋白及其他对炎症的全身反应。
N Engl J Med. 1999 Feb 11;340(6):448-54. doi: 10.1056/NEJM199902113400607.
7
Serum C-reactive protein levels in disease.疾病中的血清C反应蛋白水平
Ann N Y Acad Sci. 1982;389:406-18. doi: 10.1111/j.1749-6632.1982.tb22153.x.

C反应蛋白水平显著升高的原因及后果。

Causes and outcomes of markedly elevated C-reactive protein levels.

作者信息

Landry Alexander, Docherty Peter, Ouellette Sylvie, Cartier Louis Jacques

机构信息

Medical student at the University of Toronto in Ontario.

Assistant Professor in the Department of Rheumatology at the Moncton Hospital in New Brunswick.

出版信息

Can Fam Physician. 2017 Jun;63(6):e316-e323.

PMID:28615410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5471098/
Abstract

OBJECTIVE

To characterize the causes of marked elevation of C-reactive protein (CRP) levels, investigate patient outcomes, and examine factors that might influence the CRP response.

DESIGN

Health records were used to retrospectively determine patient characteristics, diagnoses, and outcomes over a 2-year period (2012 to 2013).

SETTING

A large referral centre in Moncton, NB.

PARTICIPANTS

Adult inpatients and outpatients with a CRP level above 100 mg/L.

MAIN OUTCOME MEASURES

Differences among the CRP distributions of various diagnosis categories were examined using Kruskal-Wallis tests, and factors affecting outcomes were examined using Fisher exact tests.

RESULTS

Over the 2-year period, 1260 CRP levels (839 patients; 3.1% of all tests) were above 100 mg/L (range 100.1 to 576.0 mg/L). The mean age was 63 years (range 18 to 101) and 50.2% of patients were men. Infection was the most prevalent cause (55.1%), followed by rheumatologic diseases (7.5%), multiple causes (5.6%), other inflammatory conditions (5.4%), malignancy (5.1%), drug reactions (1.7%), and other conditions (2.0%). A diagnosis could not be established in 17.6% of cases. On average, infections caused higher peak CRP levels ( = 34 519, < .001) and infection was present in 88.9% of cases with CRP levels greater than 350 mg/L. Rheumatologic causes were associated with only 5.6% of CRP levels above 250 mg/L. The overall mortality was 8.6% and was higher in patients with malignancy (37.0%), multiple diagnoses (21.0%), and leukopenia (20.7%, = .002).

CONCLUSION

Most patients had infections and the proportion of patients with infections increased with the level of CRP, although many diagnoses were associated with markedly elevated CRP levels. These data could help guide health care professionals in the evaluation and management of these patients.

摘要

目的

明确C反应蛋白(CRP)水平显著升高的原因,调查患者的预后情况,并研究可能影响CRP反应的因素。

设计

利用健康记录回顾性地确定患者在2年期间(2012年至2013年)的特征、诊断结果及预后情况。

地点

新不伦瑞克省蒙克顿的一家大型转诊中心。

参与者

CRP水平高于100mg/L的成年住院患者和门诊患者。

主要观察指标

使用Kruskal-Wallis检验分析不同诊断类别CRP分布的差异,使用Fisher精确检验分析影响预后的因素。

结果

在这2年期间,1260次CRP检测结果(839例患者,占所有检测的3.1%)高于100mg/L(范围为100.1至576.0mg/L)。患者平均年龄为63岁(范围为18至101岁),50.2%为男性。感染是最常见的原因(55.1%),其次是风湿性疾病(7.5%)、多种病因(5.6%)、其他炎症性疾病(5.4%)、恶性肿瘤(5.1%)、药物反应(1.7%)及其他情况(2.0%)。17.6%的病例无法确诊。平均而言,感染导致的CRP峰值水平更高(=34519,<.001),CRP水平高于350mg/L的病例中88.9%存在感染。风湿性病因仅占CRP水平高于250mg/L病例的5.6%。总体死亡率为8.6%,恶性肿瘤患者(37.0%)以及有多种诊断结果的患者(21.0%)和白细胞减少患者(20.7%,=.002)的死亡率更高。

结论

大多数患者患有感染,且感染患者的比例随CRP水平升高而增加,尽管许多诊断结果都与CRP水平显著升高有关。这些数据有助于指导医护人员对这些患者进行评估和管理。